Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: Results from a multinational electronic registry

Current Medical Research and Opinion

Volumn 25, Issue 9, 2009, Pages 2197-2206

  Olivares, J M ^a   Peuskens, J ^b   Pecenak, J ^c   Resseler, S ^d   Jacobs, A ^e   Akhras, K S ^f  

^a UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

^d SGS Medisearch International NV   (Belgium)

^e JOHNSON AND JOHNSON   (United States)

^f JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Injection; Recent diagnosis; Risperidone; Schizophrenia

Indexed keywords

LONG ACTING DRUG; RISPERIDONE;

ADULT; ARTICLE; BREAST DISEASE; CHRONIC PATIENT; CLINICAL GLOBAL IMPRESSION SCALE; CONNECTIVE TISSUE DISEASE; DISEASE SEVERITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; GENITAL SYSTEM; GENITAL SYSTEM DISEASE; GLOBAL ASSESSMENT OF FUNCTIONING; GYNECOLOGIC DISEASE; HOSPITALIZATION; HUMAN; INFECTION; INFESTATION; INFORMATION PROCESSING; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RATING SCALE; RETROSPECTIVE STUDY; SCHIZOPHRENIA; TREATMENT RESPONSE;

ADULT; AGE OF ONSET; ANTIPSYCHOTIC AGENTS; AUTOMATIC DATA PROCESSING; DELAYED-ACTION PREPARATIONS; FEMALE; FOLLOW-UP STUDIES; HEALTH RESOURCES; HUMANS; INTERNATIONALITY; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 69849112409     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903149306     Document Type: Article

References (34)

1. www.who.int/mental-health/management/schizophrenia. World Health Organization. 2008. [Last accessed: 11-13-2008]
2. Goeree R, Farahati F, Burke N, et al. The economic burden of schizophrenia in Canada in 2004. Curr Med Res Opin 2005;21:2017-2028
3. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull 2004;30:279-293
4. Oliva-Moreno J, López-Bastida J, Osuna-Guerrero R, et al. The costs of schizophrenia in Spain. Eur J Health Econ 2006; 7:179-184
5. De Hert M, Thys E, Boydens J, et al. Health care expenditure on schizophrenia patients in Belgium. Schizophr Bull 1998;24: 519-527 (Pubitemid 28524623)
6. Knapp M, King D, Pugner K, et al. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry 2004;184:509-516 (Pubitemid 38725711)
7. Almond S, Knapp M, Francois C, et al. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004; 184:346-351 (Pubitemid 38491171)
8. Wang X, Savage R BA, Rosenberg J, et al. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study. J Psychiatr Res 2006;40:669-676 (Pubitemid 44333113)
9. Lieberman J, Stroup S, McEvoy J, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223 (Pubitemid 41345943)
10. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166:152-163
11. Leucht S, Barnes T, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160:1209-1222 (Pubitemid 41070936)
12. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a metaanalysis. Lancet 2009;373:31-41
13. Lacro J, Dunn L, Dolder C, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909 (Pubitemid 35231730)
14. Robinson D, Woerner M, Alvir J, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-247 (Pubitemid 29125132)
15. McGlashan T, Johannessen J. Early detection and intervention with schizophrenia: rationale. Schizophr Bull 1996;22:201-222 (Pubitemid 26174570)
16. Loebel A, Lieberman J, Alvir J, et al. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992; 149:1183-1188
17. Lieberman J, Sheitman B, Kinon B. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 1997;17:205-229 (Pubitemid 27440642)
18. Kane J, Agugliab E, Altamurac A, et al. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 1998;8:55-66 (Pubitemid 28012861)
19. Dolder C, Lacro J, Dunn L, et al Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002;159:103-108
20. Rainer M. Risperidone long-acting injection: a review of its long term safety and efficacy. Neuropsychiatr Dis Treat 2008; 4:919-927
21. Kane J, Eerdekens M, Lindenmayer J, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-1132 (Pubitemid 41070972)
22. Parellada E, Andrezina R, Milanova V, et al. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. J Psychopharmacol 2005;19(5 Suppl):5-14 (Pubitemid 41392292)
23. Fleischhacker W, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003;64:1250-1257
24. Martin S, Libretto S, Pratt D, et al. Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone. Curr Med Res Opin 2003;19:298-305 (Pubitemid 36827838)
25. Lindenmayer J, Eerdekens E, Berry S, et al. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 2004;65:1084-1089
26. Marinis T, Saleem P, Glue P, et al. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia. Pharmacopsychiatry 2007;40: 257-263 (Pubitemid 350232817)
27. Janssen. www.risperdalconsta.com/risperdalconsta/index.html. 2008
28. Guy W. Clinical global impressions. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976
29. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV, 4th edn. Washington: American Psychiatric Association, 1994
30. McGlashan T. The profiles of clinical deterioration in schizophrenia. J Psychiatr Res 1998;32:133-141
31. Olivares J, Rodriguez-Martinez A, Burón J, et al. Cost-effectiveness analysis of switching antipsychotic medication to longacting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy 2008;6:41-53
32. Olivares J, Rodriguez-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009; In press, available online
33. Niaz O, Haddad P. Thirty-five months' experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand 2007;116:36-46 (Pubitemid 46889775)
34. Kane J, Leucht S, Carpenter D, et al. Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 2003;64 (Suppl 12):5-48